Product
TACE combined with sorafenib + PD-1 mAb
1 clinical trial
8 indications
Indication
Hepatocellular CarcinomaIndication
Liver CancerIndication
Digestive System NeoplasmsIndication
SorafenibIndication
Liver DiseaseIndication
Antineoplastic AgentsIndication
Protein Kinase InhibitorsClinical trial
TACE Combined With Sorafenib and PD-1 mAb in the Treatment of BCLC B/C Hepatocellular Carcinoma: Single Arm, Single Center, Open Label StudyStatus: Completed, Estimated PCD: 2022-07-31